for the participation in the conference. While the late registration is allowed till March 25th, the individuals who are much interested but couldn’ t register could also do so by on spot registration at the venue itself on March 26th. The organizers can be contacted at ibem2017 @ gmail. com.
The students, post-doctoral fellows and faculty members who are looking for conceptual clarity and technological advancements in the field can attend it. The organizers have also called for attention from industry to showcase the latest advances besides highlight challenges. The flyer of the conference can be accessed here. More details on the conference website here.
US-FDA ACCEPTS MYLAN & BIOCON’ S JOINT APPLICATION ON BIOSIMILAR TRASTUZUMAB
Biocon and Mylan have announced that the United States Food and Drug Administration( FDA) has accepted Mylan’ s biologics license
application( BLA) for MYL- 1401O, a proposed biosimilar trastuzumab, for filing through the 351( k) pathway. This product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2- positive breast cancers. The anticipated FDA goal date set under the Biosimilar User Fee Act( BsUFA) is September 03, 2017.
Mylan’ s President, Mr Rajiv Malik commented:“ The FDA acceptance of our BLA for proposed biosimilar trastuzumab marks an important step toward increasing access to this treatment option for patients in the U. S. We believe that our comprehensive package of analytical similarity, non-clinical and clinical data submitted with the BLA will demonstrate similarity of the proposed biosimilar trastuzumab to the reference product.”
BIOASIA 2017 TO BRING
TOGETHER TOP GLOBAL PHARMA POWERHOUSES TO HYDERABAD
BioAsia, the annual flagship event of the Government of Telangana has over the years emerged as a preeminent technology and bio-business convention in Asia for Life sciences, pharmaceuticals and healthcare. Organized by the Department of Industries and Commerce, Government of Telangana, the 14 th Edition of BioAsia is expected to bring together eminent industry leaders from across the globe. Demonstrating its dominant position, the event scheduled for February 6-8, 2017 is all set to bring together some of the most influential global corporate leaders to Hyderabad which is being termed as the life sciences hub of India.
While announcing the speakers for the event, Mr Shakthi Nagappan, CEO, BioAsia said,“ In its journey of 14 years, the flagship event of
Telangana- BioAsia has emerged as the largest Life Science event in India and one of the pre-eminent meetings in Asia. With continued commitment of the State Government to Life Sciences sector, BioAsia 2017 is expected to be bigger and will witness participation of life sciences and healthcare leaders from over 50 Countries”.
BECTON DICKINSON LAUNCHES REAGENTS TO SIMPLIFY SINGLE CELL RESEARCH
BD( Becton, Dickinson and Company), a leading global medical technology company, on February 19, 2017, announced the commercial availability of its new kits that provide an easier method to identify and quantify genetic information in individual cells for genomics-based research.
The process of whole transcriptome analysis( WTA) is typically used by researchers in the discovery phase to determine if an under- or over-expression of
biotech certain genes are indicative of a specific set of physical characteristics, or phenotype. Being able to quantify RNA molecules that comprise genes is a critical early stage process to determine what makes healthy cells different from diseased cells, for example, or to gain a greater understanding of the underlying causes of cell differentiation.
BIOVOICENEWS. COM 47